Survival analysis showed that low abundance of 12 of these 15 immunomodulators (all except for CD27, CD28, and CD40LG) was associated with poor prognosis in patients with BLCA (Supplementary Figure S5). Here, CD27 is linked to bladder transitional cell carcinoma.